UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q1 2021 Earnings Conference Call May 17, 2021 5:00 PM ET Company Participants Dane Andreeff - Interim President & Chief Executive Officer Mark Leno - Vice President & General Manager, Canadian Operations Joyce LaViscount - Chief Financial Officer & Chief Operating Officer Conference Call Participants Joe Gomes - Noble Capital Operator Please standby. Good evening ladies and gentlemen and welcome to the First Quarter Fiscal Year 2021 Earnings Conference Call fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) Delaware 36-4787690 (State or other jurisdictio ...

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q4 2020 Earnings Conference Call March 10, 2021 5:00 PM ET Company Participants Dane Andreeff - Interim President & Chief Executive Officer Mark Leno - Vice President & General Manager, Canadian Operations Joyce LaViscount - Chief Financial Officer & Chief Operating Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Anthony Lamport - Lambda Fund Management Mark Palin - AALRR Operator Please standby. Good evening ladies and gentlemen, and w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from _____ to _____ Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 36-4787690 (State or other juris ...

Empowering the Healing Process of the Brain Disruptive Technology for Healthcare (NASDAQ:HSDT | TSX:HSM) Legal Disclaimers This presentation contains forward-looking statements, including statements about: uncertainties regarding the FDA regulatory approval process (including the FDA Breakthrough Designation), uncertainties regarding the regulatory approval process in China and Australia, whether the results of our clinical trials will be sufficient to support an FDA, CE Mark or TGA approval of the PoNS™ de ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2020 was $131,000, a decrease from $150,000 in Q3 2019, primarily driven by sales to neurotherapy clinics in Canada impacted by COVID-19 [18][19] - Gross profits increased by $48,000 or 79% year-over-year to $109,000 due to a temporary reduction in manufacturing activity [26] - Operating expenses decreased by $2 million or 35% year-over-year to $3.8 million, reflecting cost reduction initiatives [26] - Operating loss for Q3 2020 was $3.7 million compared to $5.7 million for the prior year [27] - Net loss for Q3 2020 was $3.5 million or $0.08 per share, compared to a net loss of $5.6 million or $0.22 per share in the same period last year [27] Business Line Data and Key Metrics Changes - Sales performance in Canada continued to be impacted by COVID-19, with clinics operating at approximately 50% of normal capacity due to federal and provincial restrictions [19][20] - The number of authorized PoNS clinic locations increased from 7 to 27 in less than a year, nearly a fourfold increase [22] Market Data and Key Metrics Changes - The regulatory strategy focuses on obtaining clearance for the PoNS device for multiple sclerosis (MS), with a submission made on August 4, 2020 [12][13] - The FDA requested additional information on October 19, 2020, which the company is preparing to address [14][15] Company Strategy and Development Direction - The company aims to reposition itself for growth by focusing on regulatory approval in the U.S. and expanding its commercial activities in Canada [9][32] - Future plans include leveraging the PoNS device as a platform technology for new indications in stroke, cerebral palsy, and wellness applications [32] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by COVID-19 but expressed confidence in the company's ability to progress on regulatory and commercial initiatives [31] - The company is committed to maintaining a disciplined approach to spending while exploring options to secure additional capital [29][30] Other Important Information - As of September 30, 2020, the company had $2.7 million in cash, down from $5.5 million at the end of 2019, with no outstanding debt [28] - A private placement closed on October 26, 2020, resulting in net proceeds of approximately $3.2 million [29] Q&A Session Summary Question: Why hasn't the company considered PoNS for Parkinson's? - Management indicated that while there is potential for the PoNS device in treating Parkinson's, the current focus is on indications with existing data. Future broader indications across multiple disease states are being considered [37]

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 36-4787690 (State or other jurisdi ...

The Last Frontier in Healthcare Empowering the Natural Healing Process of the Brain September 2020 LegalDisclaimers This presentation contains forward-looking statements, including statements about: uncertainties regarding the FDA regulatory approval process, whether the results of our clinical trials will be sufficient to support an FDA, CE Mark or TGA approval of the PoNS™ device for marketing or whether the agencies may require that the Company conduct future clinical trials; future economic, competitive ...

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q2 2020 Results Conference Call August 12, 2020 5:00 PM ET Company Participants Phil Deschamps - Chairman, President & Chief Executive Officer Joyce LaViscount - Chief Financial Officer & Chief Operations Officer Conference Call Participants Steven Lichtman - Oppenheimer & Company Ben Haynor - Alliance Global Partners Operator Good evening, ladies and gentlemen, and welcome to the Second Quarter of Fiscal Year 2020 Earnings Conference Call for Helius Medical T ...